0001209191-23-047971.txt : 20230901 0001209191-23-047971.hdr.sgml : 20230901 20230901164547 ACCESSION NUMBER: 0001209191-23-047971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230831 FILED AS OF DATE: 20230901 DATE AS OF CHANGE: 20230901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sandborn William J. CENTRAL INDEX KEY: 0001923805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 231233147 MAIL ADDRESS: STREET 1: C/O VENTYX BIOSCIENCES, INC. STREET 2: 662 ENCINITAS BLVD. STE 250 CITY: ENCINITAS STATE: CA ZIP: 92024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12790 EL CAMINO REAL, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-31 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001923805 Sandborn William J. C/O VENTYX BIOSCIENCES, INC. 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 0 1 0 0 See Remarks 0 Common Stock 2023-08-31 4 M 0 11900 14.85 A 60289 D Common Stock 2023-08-31 4 S 0 11900 33.6432 D 48389 D Common Stock 24194 I By Spouse Stock Option (Right to Buy) 14.85 2023-08-31 4 M 0 11900 0.00 D 2032-05-09 Common Stock 11900 664300 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022. Represents the weighted average share price of an aggregate total of 11,900 shares sold in the price range of $33.35 to $34.1159. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022. President and Chief Medical Officer /s/ Christopher Krueger, as Attorney-in-Fact 2023-09-01